{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:54:58Z","timestamp":1793876098551,"version":"4.7.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural Program, National Cancer Institute, National Institutes of Health."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increased sarcoma and melanoma risks after hereditary retinoblastoma are well established, whereas less is known about epithelial subsequent malignant neoplasms (SMNs) and risks for multiple (\u22652) SMNs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Leveraging long-term follow-up and detailed histologic information, we quantified incident SMN risk among 1128 hereditary and 924 nonhereditary retinoblastoma survivors (diagnosed 1914\u20132006; follow-up through 2016). Standardised incidence ratios (SIRs) compared cancer risk after retinoblastoma relative to the general population. We estimated cumulative incidence accounting for competing risk of death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hereditary survivors had statistically significantly increased SMN risk (<jats:italic>N<\/jats:italic>\u2009=\u2009239; SIR\u2009=\u200911.9; 95% confidence interval [CI] 10.4\u201313.5), with SIRs &gt;80-fold for sarcomas, nasal cavity tumours and pineoblastoma. Significantly increased risks were also observed for melanoma and central nervous system, oral cavity and breast SMNs (SIRs\u2009=\u20093.1\u201317), but not the uterus, kidney, lung, bladder, pancreas or other types. Cumulative incidence 50 years following hereditary retinoblastoma was 33.1% (95% CI 29.0\u201337.2) for a first SMN and 6.0% (95% CI 3.8\u20138.2) for a second SMN. SMN risk was not increased after nonhereditary retinoblastoma (<jats:italic>N<\/jats:italic>\u2009=\u200925; SIR\u2009=\u20090.8; 95% CI 0.5\u20131.2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Beyond the established sarcoma and melanoma risks after hereditary retinoblastoma, we demonstrate increased risk for a more limited number of epithelial malignancies than previously suggested. Cumulative incidence estimates emphasise long-term SMN burden after hereditary retinoblastoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-01248-y","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:06:31Z","timestamp":1611187591000},"page":"1312-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-4647","authenticated-orcid":false,"given":"Sara J.","family":"Schonfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-2478","authenticated-orcid":false,"given":"Ruth A.","family":"Kleinerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-6773","authenticated-orcid":false,"given":"Margaret A.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/jnci\/djn394","volume":"100","author":"T Marees","year":"2008","unstructured":"Marees, T., Moll, A. C., Imhof, S. M., de Boer, M. R., Ringens, P. J. & van Leeuwen, F. E. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J. Natl Cancer Inst. 100, 1771\u20131779 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/bjc.2013.228","volume":"108","author":"A MacCarthy","year":"2013","unstructured":"MacCarthy, A., Bayne, A. M., Brownbill, P. A., Bunch, K. J., Diggens, N. L., Draper, G. J. et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br. J. Cancer 108, 2455\u20132463 (2013).","journal-title":"Br. J. Cancer"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2013.54.7844","volume":"32","author":"JR Wong","year":"2014","unstructured":"Wong, J. R., Morton, L. M., Tucker, M. A., Abramson, D. H., Seddon, J. M., Sampson, J. N. et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J. Clin. Oncol. 32, 3284\u20133290 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.26193","volume":"64","author":"P Temming","year":"2017","unstructured":"Temming, P., Arendt, M., Viehmann, A., Eisele, L., Le Guin, C. H., Schundeln, M. M. et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: a report from the German reference center. Pediatr. Blood Cancer 64, 71\u201380 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1200\/JCO.2005.05.054","volume":"23","author":"RA Kleinerman","year":"2005","unstructured":"Kleinerman, R. A., Tucker, M. A., Tarone, R. E., Abramson, D. H., Seddon, J. M., Stovall, M. et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272\u20132279 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1248_CR6","first-page":"454","volume":"81","author":"DH Abramson","year":"1976","unstructured":"Abramson, D. H., Ellsworth, R. M. & Zimmerman, L. E. Nonocular cancer in retinoblastoma survivors. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 81, 454\u2013457 (1976).","journal-title":"Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol."},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jama.1997.03550150066037","volume":"278","author":"FL Wong","year":"1997","unstructured":"Wong, F. L., Boice, J. D. Jr., Abramson, D. H., Tarone, R. E., Kleinerman, R. A., Stovall, M. et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278, 1262\u20131267 (1997).","journal-title":"JAMA"},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jnci\/djh058","volume":"96","author":"O Fletcher","year":"2004","unstructured":"Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M. & Peto, J. Lifetime risks of common cancers among retinoblastoma survivors. J. Natl Cancer Inst. 96, 357\u2013363 (2004).","journal-title":"J. Natl Cancer Inst."},{"key":"1248_CR9","unstructured":"Howlader, N., Noone, A., Krapcho, M., Miller, D., Brest, A., Yu, M. et al. SEER Cancer Statistics Review, 1975\u20132016 (National Cancer Institute, Bethesda, 2019)."},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.19.01096","volume":"37","author":"RA Kleinerman","year":"2019","unstructured":"Kleinerman, R. A., Schonfeld, S. J., Sigel, B. S., Wong-Siegel, J. R., Gilbert, E. S., Abramson, D. H. et al. Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation. J. Clin. Oncol. 37, 3436\u20133445 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.2011.34.6585","volume":"29","author":"GT Armstrong","year":"2011","unstructured":"Armstrong, G. T., Liu, W., Leisenring, W., Yasui, Y., Hammond, S., Bhatia, S. et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056\u20133064 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","volume":"124","author":"AM van Eggermond","year":"2014","unstructured":"van Eggermond, A. M., Schaapveld, M., Lugtenburg, P. J., Krol, A. D., de Boer, J. P., Zijlstra, J. M. et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood 124, 319\u2013327 (2014). quiz 466.","journal-title":"Blood"},{"key":"1248_CR13","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/S0161-6420(01)00713-8","volume":"108","author":"DH Abramson","year":"2001","unstructured":"Abramson, D. H., Melson, M. R., Dunkel, I. J. & Frank, C. M. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108, 1868\u20131876 (2001).","journal-title":"Ophthalmology"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ejca.2010.03.029","volume":"46","author":"T Marees","year":"2010","unstructured":"Marees, T., van Leeuwen, F. E., Schaapveld, M., Imhof, S. M., de Boer, M. R., Kors, W. A. et al. Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur. J. Cancer 46, 2052\u20132058 (2010).","journal-title":"Eur. J. Cancer"},{"key":"1248_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ophtha.2019.10.040","volume":"127","author":"MC de Jong","year":"2020","unstructured":"de Jong, M. C., Kors, W. A., Moll, A. C., de Graaf, P., Castelijns, J. A., Jansen, R. W. et al. Screening for pineal trilateral retinoblastoma revisited: a meta-analysis. Ophthalmology 127, 601\u2013607 (2020).","journal-title":"Ophthalmology"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/1097-0142(197705)39:5<2048::AID-CNCR2820390522>3.0.CO;2-9","volume":"39","author":"FA Jakobiec","year":"1977","unstructured":"Jakobiec, F. A., Tso, M. O., Zimmerman, L. E. & Danis, P. Retinoblastoma and intracranial malignancy. Cancer 39, 2048\u20132058 (1977).","journal-title":"Cancer"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.1999.17.6.1829","volume":"17","author":"T Kivela","year":"1999","unstructured":"Kivela, T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J. Clin. Oncol. 17, 1829\u20131837 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley, T. A., Leisenring, W., Crowley, J. & Storer, B. E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 18, 695\u2013706 (1999).","journal-title":"Stat. Med."},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/bjc.2014.193","volume":"110","author":"MP Little","year":"2014","unstructured":"Little, M. P., Schaeffer, M. L., Reulen, R. C., Abramson, D. H., Stovall, M., Weathers, R. et al. Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study. Br. J. Cancer 110, 2623\u20132632 (2014).","journal-title":"Br. J. Cancer"},{"key":"1248_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy227","author":"RA Kleinerman","year":"2019","unstructured":"Kleinerman, R. A., Tucker, M. A., Sigel, B. S., Abramson, D. H., Seddon, J. M. & Morton, L. M. Patterns of cause-specific mortality among 2053 survivors of retinoblastoma, 1914-2016. J. Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djy227 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1248_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10689-011-9505-3","volume":"11","author":"CJ Dommering","year":"2012","unstructured":"Dommering, C. J., Marees, T., van der Hout, A. H., Imhof, S. M., Meijers-Heijboer, H., Ringens, P. J. et al. RB1 mutations and second primary malignancies after hereditary retinoblastoma. Fam. Cancer 11, 225\u2013233 (2012).","journal-title":"Fam. Cancer"},{"key":"1248_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejmg.2018.07.017","volume":"62","author":"A Chaussade","year":"2019","unstructured":"Chaussade, A., Millot, G., Wells, C., Brisse, H., Lae, M., Savignoni, A. et al. Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy. Eur. J. Med. Genet. 62, 217\u2013223 (2019).","journal-title":"Eur. J. Med. Genet."},{"key":"1248_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ygyno.2011.10.019","volume":"124","author":"JH Francis","year":"2012","unstructured":"Francis, J. H., Kleinerman, R. A., Seddon, J. M. & Abramson, D. H. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. Gynecol. Oncol. 124, 254\u2013259 (2012).","journal-title":"Gynecol. Oncol."},{"key":"1248_CR24","unstructured":"Berrington de Gonzalez, A. B., Bouville, A. & Rajaraman, P. in Schottenfeld and Fraumeni: Cancer Epidemiology and Prevention (ed. Thun, M. J.) 227\u2013248 (Oxford University Press, New York, 2018)."},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IIO.0000000000000266","volume":"59","author":"DH Abramson","year":"2019","unstructured":"Abramson, D. H., Francis, J. H. & Gobin, Y. P. What\u2019s new in intra-arterial chemotherapy for retinoblastoma? Int. Ophthalmol. Clin. 59, 87\u201394 (2019).","journal-title":"Int. Ophthalmol. Clin."},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/eye.2012.175","volume":"27","author":"CL Shields","year":"2013","unstructured":"Shields, C. L., Fulco, E. M., Arias, J. D., Alarcon, C., Pellegrini, M., Rishi, P. et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye 27, 253\u2013264 (2013).","journal-title":"Eye"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01248-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T01:03:58Z","timestamp":1642727038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01248-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,3,30]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01248-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Special Studies Institutional Review Board at the National Cancer Institute, including informed consent for questionnaires from survivors or their legal guardians for survivors <18 years of age. This study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All anonymised data used in the paper can be provided upon request upon application to the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was supported by the Intramural Programme, National Cancer Institute, National Institutes of Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}